£2.0M
The pre-series a financing was led by Science Angel Syndicate and Fink Family Office to support pre-clinical studies for the GRACE implant.
Catapult
Venture CapitalCatapult Ventures is an independent venture capital fund manager that has invested in UK businesses since 2002.
Portfolio
7
companies
By category
- HealthTech£10.5M
- BioTech£2.6M
- MedTech£2.5M
- AI/ML£530K
By location
- United Kingdom£10.5M
- Manchester£3.7M
- Cheshire£2.0M
Portfolio companies
F
Flynotes
Flynotes provides a digital healthcare consent platform for medical and dental treatment.
H
Healum
Healum develops AI powered patient management software for healthcare professionals.
Monument Therapeutics
Monument Therapeutics develops stratified treatments for central nervous system conditions using digital brain biomarkers.
M
MyHelp
MyHelp builds digital solutions for mental health service providers and patients.
PC
Pill Connect
Pill Connect builds digital tracking devices to monitor medication adherence in clinical trials.
QV Bioelectronics
QV Bioelectronics builds surgically implanted electric field therapy devices to treat brain tumours.
View all 7 companiesShow fewer
Team
Emma Johnson
Associate
Emma brings life sciences investment experience from roles at Catapult Ventures and the British Business Bank. She also holds board and observer experience across several therapeutics companies.
CS
Chris Spencer
Venture Partner
Chris brings health tech and venture experience from roles including health tech CEO, non-executive chair, and venture partner at Catapult. He also maintains involvement in the arts as a chorus bass with the Royal Scottish National Orchestra.
VC
Vijay Curthan
Investment Director
Vijay brings investment and private equity experience from roles at Catapult Ventures Group, Magdalene Capital, and QG Investments. He previously held positions at Investment Corporation of Dubai and Oman Investment Authority.
LinkedInRecent investments
£2.6M
Catapult Ventures led the seed round alongside Neo Kuma Ventures, Wren Capital, and o2H ventures to support the Cambridge Cognition spinout.
"By establishing Monument Therapeutics, we have created an exciting new venture to develop stratified medicine in CNS drug development that could help many patients with unmet clinical needs. It leverages Cambridge Cognition’s intellectual property and provides the potential for considerable royalty payments in the future, while the Company continues to focus on the development and commercialisation of its cutting-edge digital health technologies."
£530K
The digital health company raised the capital to scale its AI powered patient management platform and support remote care programmes.
"Greater Manchester is the only place in the UK that can provide us the data partnerships, research support, diverse population and integrated health and social care practices that will enable us to give healthcare professionals the control and trust in the unbiased intelligence that powers our patient management system."
£10.4M
The digital healthcare consent platform has secured backing from Maven and Catapult to fund product development and international growth.
"We are really pleased to welcome Maven and the angel investors alongside our existing shareholders."
£510K
The funding round was backed by Jonathan Milner, Catapult Ventures and Shallcross Partners to fund regulatory submissions and commercialisation.